AstraZeneca PLC (NASDAQ:AZN) Shares Bought by TD Private Client Wealth LLC

TD Private Client Wealth LLC lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 58.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,808 shares of the company’s stock after acquiring an additional 6,201 shares during the quarter. TD Private Client Wealth LLC’s holdings in AstraZeneca were worth $1,101,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Albion Financial Group UT grew its stake in shares of AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after purchasing an additional 248 shares during the period. Groupama Asset Managment boosted its holdings in AstraZeneca by 22.9% during the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after buying an additional 101,225 shares in the last quarter. Versant Capital Management Inc grew its position in AstraZeneca by 2,618.5% during the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock worth $48,000 after buying an additional 707 shares during the period. Crews Bank & Trust purchased a new position in AstraZeneca in the fourth quarter valued at about $55,000. Finally, Golden State Wealth Management LLC acquired a new stake in shares of AstraZeneca during the 4th quarter valued at approximately $55,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on AZN. Morgan Stanley initiated coverage on AstraZeneca in a report on Wednesday, February 12th. They issued an “overweight” rating on the stock. UBS Group raised AstraZeneca from a “neutral” rating to a “buy” rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Trading Down 2.1 %

Shares of AZN opened at $74.93 on Monday. AstraZeneca PLC has a fifty-two week low of $62.75 and a fifty-two week high of $87.68. The company has a market capitalization of $232.37 billion, a PE ratio of 33.16, a price-to-earnings-growth ratio of 1.42 and a beta of 0.41. The stock has a fifty day moving average of $72.83 and a two-hundred day moving average of $71.91. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. As a group, analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Monday, March 24th. Investors of record on Friday, February 21st will be issued a $1.03 dividend. This represents a yield of 2%. This is an increase from AstraZeneca’s previous semi-annual dividend of $0.49. The ex-dividend date of this dividend is Friday, February 21st. AstraZeneca’s payout ratio is presently 91.15%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.